Navigation Links
NeoStem Provides Third Quarter Update
Date:11/12/2010

NEW YORK, Nov. 12, 2010 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"),  an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units, U.S. adult stem cells, China adult stem cells, and China pharmaceuticals, is today providing results of its third quarter 2010.

Third Quarter Results

  • Revenues for the nine months ended September 30, 2010 were $51.7 million, compared to $157,700 for the comparable period of 2009.  Revenues for the three months ended September 30, 2010 were $16.5 million compared to $85,100 for the same period in 2009.
  • For the nine months ended September 30, 2010 revenues increased 14% over the 2009 pro forma revenue of $45 million.
  • Net cash used in operating activities for the nine months ended September 30, 2010 was $3.2 million compared to $9.5 million for the comparable period in 2009.  
  • During the first nine months of 2010, the Company invested $12.5 million in capital expenditures primarily related to our continuing expansion into China.

  • In early 2010, Erye began relocating its operations to its new state-of-the-art manufacturing facility.  While the facility is not yet operating at peak efficiency, it has already begun to see increased production from the two cGMP approved lines for the manufacturing of penicillin and cephalosporin powder for injection that have historically accounted for over 70% of Erye's revenues. At its peak, the new facility is expected to provide an increase in production capacity of more than 50% over the old facility.

    Additionally, the Company has begun to generate revenues from its pipeline of licensed stem cell-based regenerative medicine therapies; a key element of NeoStem's growth strategy in both the United States and China. Recently, the local authority in charge of pricing for public medical services in China approved pricing and eligibility for patients to receive reimbursement for up to 80% of the cost of an orthopedic procedure under the new technology category being administered at a leading specialist orthopedic hospital in China.  This approval is a significant milestone that the Company believes will fuel its revenues from such activities and facilitate the execution of similar arrangements with other specialist hospitals in China in the near future.

    Full financial information for the third quarter can be found in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 which may be found at www.sec.gov.

    About NeoStem, Inc.NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .

    Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's strategy, accelerating Erye's sales growth in 2010 and successful transfer of Erye's production lines to the new facility, growth in revenues from the Company's China operations, as well as other advances in the Company's business, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.For more information, please contact:NeoStem, Inc.Robin Smith, CEOPhone: +1-212-584-4174Email: rsmith@neostem.comWeb:   http://www.neostem.com
    '/>"/>

    SOURCE NeoStem, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. NeoStem to Present at LifeTech Capital Miami Medical Investors Conference
    2. Local Chinese Government Authorities Approve Pricing and Reimbursement for NeoStems Licensed Adult Stem Cell Treatments for Orthopedic Applications in China
    3. NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California
    4. NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement
    5. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
    6. NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
    7. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
    8. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
    9. NeoStem Announces Warrant Exercise by Principal Shareholder
    10. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
    11. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent ... as the number one company for hearing aids, ranking it ... fifteen other brands. ... Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, ...
    (Date:9/7/2017)... 7, 2017  Eli Lilly and Company (NYSE: ... streamline operations to more efficiently focus resources on ... structure. Global workforce reductions, including those from a ... impact approximately 3,500 positions. With ... savings of approximately $500 million that will begin ...
    (Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , ... and marketer of proprietary clinical grade cell and tissue ... announces that Mike Rice , President and CEO, will ... Rodman & Renshaw 19 th Annual ... Eastern time (12:25 p.m. Pacific time). The conference is being ...
    Breaking Medicine Technology:
    (Date:9/22/2017)... PITTSBURGH, PA (PRWEB) , ... September 22, 2017 ... ... as soon as possible, and they often saves lives. However, if one isn’t ... order to widen the availability of defibrillation, I came up with this idea," ...
    (Date:9/22/2017)... ... 22, 2017 , ... After a long health ordeal that ... lease on life with assistance from CreditAssociates. CreditAssociates provides debt relief and debt ... debt. The senior is one of the satisfied clients who expressed their appreciation ...
    (Date:9/22/2017)... ... September 22, 2017 , ... Happy Living’s mission - to improve ... carries it into the entertaining and delicious worlds of theatre and wines. , ... Living) convinced him to turn his play into a book. The Greener The Grass ...
    (Date:9/22/2017)... ... September 22, 2017 , ... TopConsumerReviews.com ... by Native Remedies that helps promote pancreatic health and regulate blood sugar ... some prescription-based approaches can have negative side effects, and with the changes in ...
    (Date:9/22/2017)... ... September 22, 2017 , ... ... brush more effectively even on the go. Their electric toothbrushes aggressively attack oral ... inflammation, with UV sanitizing technology. Combining leading edge Enke technology with a premium ...
    Breaking Medicine News(10 mins):